Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.

ABSTRACT:

Importance

Anti-vascular endothelial growth factor (VEGF) injections in eyes with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) reduce development of vision-threatening complications from diabetes over at least 2 years, but whether this treatment has a longer-term benefit on visual acuity is unknown.

Objective

To compare the primary 4-year outcomes of visual acuity and rates of vision-threatening complications in eyes with moderate to severe NPDR treated with intravitreal aflibercept compared with sham. The primary 2-year analysis of this study has been reported.

Design, setting, and participants

Randomized clinical trial conducted at 64 clinical sites in the US and Canada from January 2016 to March 2018, enrollin

SUBMITTER: Maturi RK 

PROVIDER: S-EPMC10408259 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature